Table 3 Patient characteristics and patient-reported outcomes scores at randomization. Kd; Carfilzomib-dexamethsone, IQR; Interquartile range 25-75%, MM; multiple myeloma, ASCT; high-dose melphalan with autologous stem-cell transplantation, WHO; World health organization, EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core questionnaire; EORTC QLQ‐MY20, European Organisation for Research and Treatment of Cancer Multiple Myeloma module; FACT/GOG‐ntx subscale, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity subscale; SD, Standard deviation

Median age, years (IQR)

60 (54–65)

63 (58–67)

Gender Female/Male

39/43

32/54

Median time from MM diagnosis, months (IQR)

47 (37–65)

48 (37–60)

Median time from salvage ASCT to randomization, weeks (IQR)

8.1 (7.7–8.5)

8.1 (7.8–8.8)

Median time from salvage ASCT to start of Kd maintenance/observation, weeks (IQR)

9.8 (8.8–10.3)

10.8 (8.8–13.7)

Myeloma status

Stringent complete response

Complete response

Very good partial response

Partial response

Stable disease

Progressive disease

Missing

10 (12%)

13 (16%)

41 (50%)

16 (20%)

1 (1%)

0 (0%)

1 (1%)

12 (14%)

8 (9%)

50 (58%)

16 (19%)

0 (0%)

0 (0%)

0 (0%)

WHO performance status

0

1

2

3 or 4

Missing

47 (57%)

29 (35%)

2 (2%)

0 (0%)

4 (5%)

45 (52%)

30 (35%)

2 (2%)

0 (0%)

9 (10%)

Country of residence

Denmark

Sweden

Norway

Finland

Lithuanian

26 (30%)

18 (21%)

32 (37%)

4 (5%)

6 (7%)

21 (26%)

28 (34%)

20 (24%)

4 (5%)

9 (11%)

EORTC QLQ-C30 domain scores, mean (SD)

Global Health Status/Quality of life

66.0 (22.3)

68.1 (18.8)

Physical functioning

77.4 (19.9)

75.9 (20.0)

Role functioning

65.6 (29.5)

63.0 (29.6)

Emotional functioning

80.1 (21.3)

85.8 (17.9)

Cognitive functioning

84.8 (18.3)

82.3 (21.7)

Social functioning

74.1 (24.6)

73.6 (25.4)

Fatigue

35.6 (24.2)

35.6 (21.4)

Nausea/vomiting

7.7 (14.4)

9.0 (18.9)

Pain

22.9 (25.4)

25.2 (27.8)

Dyspnea

23.2 (25.0)

25.6 (25.7)

Insomnia

23.5 (26.4)

23.5 (25.8)

Appetite loss

13.0 (21.7)

16.2 (25.6)

Constipation

9.0 (19.1)

7.8 (19.4)

Diarrhea

17.9 (24.4)

19.7 (26.8)

Financial difficulties

16.2 (26.7)

8.6 (21.9)

EORTC QLQ-MY20 domain scores, mean (SD)

Disease symptoms

17.5 (16.9)

17.3 (17.5)

Side effects of treatment

22.2 (14.2)

20.2 (15.2)

Future perspective

58.9 (29.1)

62.0 (25.9)

Body image

68.4 (30.3)

70.2 (32.7)

FACT/GOG-ntx domain score, mean (SD)

FACT/GOG-ntx subscale

38.1 (6.7)

38.7 (5.0)